Improved Long-Term Outcomes After Resection of Pancreatic Adenocarcinoma: A Comparison Between Two Time Periods

Annals of Surgical Oncology

Volumn 22, Issue 4, 2015, Pages 1160-1167

  Serrano, Pablo E ^a   Cleary, Sean P ^b,e   Dhani, Neesha ^c,e   Kim, Peter T W ^d   Greig, Paul D ^b,e   Leung, Kenneth ^b   Moulton, Carol Anne ^b,e   Gallinger, Steven ^b,e   Wei, Alice C ^b,e,f  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA IN SITU; ADENOSQUAMOUS CARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVOR; COMPARATIVE STUDY; FEMALE; HIGH VOLUME HOSPITAL; HUMAN; INTRADUCTAL MUCINOUS PANCREATIC NEOPLASMS; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATIC ADENOSQUAMOUS; PHASE 2 CLINICAL TRIAL; RETROSPECTIVE STUDY; SHORT TERM SURVIVAL; SURGICAL MORTALITY; TREATMENT OUTCOME; ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; FOLLOW UP; LYMPH NODE; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TIME; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 84925491158     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4196-2     Document Type: Article

References (38)

1. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA. 1998;280:1747–51.
2. Ghaferi AA, Osborne NH, Birkmeyer JD, Dimick JB. Hospital characteristics associated with failure to rescue from complications after pancreatectomy. J Am Coll Surg. 2010;211:325–30.
3. Ghaferi AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated with inpatient surgery. N Engl J Med. 2009;361:1368–75.
4. McNulty NJ, Francis IR, Platt JF, Cohan RH, Korobkin M, Gebremariam A. Multi–detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and pancreatic adenocarcinoma. Radiology. 2001;220:97–102.
5. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727–33.
6. House MG, Yeo CJ, Cameron JL, et al. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg. 2004;8:280–8.
7. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–81.
8. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.
9. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903.
10. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.
11. Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol. 2012;19:169–75.
12. He J, Ahuja N, Makary MA, et al. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. HPB (Oxford). 2014;16:83–90.
13. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
14. Riall TS, Nealon WH, Goodwin JS, Zhang D, Kuo YF, Townsend CM Jr, et al. Pancreatic cancer in the general population: Improvements in survival over the last decade. J Gastrointest Surg. 2006;10:1212–23; discussion 1223-1214.
15. Sohal DP, Walsh RM, Ramanathan RK, Khorana AA. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 2014;106:dju011.
16. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.
17. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
18. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–03.
19. Yu XJ. Nab-paclitaxel combined with gemcitabine as adjuvant therapy for pancreatic cancer after curative resection (No) [ClinicalTrials.gov identifier NCT02023021]. US National Institutes of Health, ClinicalTrials.gov. http://www.clinicaltrials.gov.
20. UNICANCER. Trial comparing adjuvant chemotherapy with gemcitabine versus mFolfirinox to treat resected pancreatic adenocarcinoma. [ClinicalTrials.gov identifier NCT01526135]. US National Institutes of Health, ClinicalTrials.gov. http://www.clinicaltrials.gov.
21. Kim EJ, Ben-Josef E, Herman JM, et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013;119:2692–700.
22. Barugola G, Partelli S, Crippa S, Capelli P, D’Onofrio M, Pederzoli P, et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 2012;203:,132–39.
23. Katz MH, Marsh R, Herman JM et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20:2787–95.
24. Leone F, Gatti M, Massucco P, et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer. 2013;119:277–84.
25. Edge SB, Byrd DR, Compton CC, et al. Exocrine and endocrine pancreas. AJCC cancer staging manual. 7th ed. New York: Springer; 2010:241–49.
26. Sobin LG, Wittekind C. TNM classification of malignant tumours. 7th ed. Oxford: Wiley; 2010.
27. Mills M. Introducing survival and event history analysis. 2011:81–93.
28. Simons JP, Ng SC, McDade TP, Zhou Z, Earle CC, Tseng JF. Progress for resectable pancreatic [corrected] cancer? A population-based assessment of US practices. Cancer. 2010;116:1681–90.
29. Langer B. Role of volume outcome data in assuring quality in HPB surgery. HPB (Oxford). 2007;9:330–4.
30. Marcaccio M, LB, Rumble B, Hunter A; Expert Panel on HPB Surgical Oncology. Hepatic, pancreatic and biliary tract (HPB) surgical oncology standards. 2006. http://www.cancercare.on.ca. Accessed 2 Oct 2014.
31. Simunovic M, Urbach D, Major D, et al. Assessing the volume-outcome hypothesis and region-level quality improvement interventions: pancreas cancer surgery in two Canadian provinces. Ann Surg Oncol. 2010;17:2537–44.
32. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.
33. Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg. 2007;142:767–74; discussion 773-764.
34. Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008;15:165–74.
35. Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009;13:1337–44.
36. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576–85.
37. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74–85.
38. Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32:504–12.